Clinical trial · Interventional
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
Phase II Study of VCD/IE in the Treatment of the Patients With Ewing's Sarcoma Family of Tumors
NCT00568464CI-TRIAL-00002429terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The enrollment is slower than expected
Summary
Brief summary (as posted)
The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ewing's Sarcoma | Ewing Sarcoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VCR, CTX, ADM; IFO, VP-16 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: VCR, CTX, ADM; IFO, VP-16
Primary outcomes (1)
- measure
- Response Rate
- timeFrame
- every two cycles
Secondary outcomes (1)
- measure
- Toxicity
- timeFrame
- every cycle
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age range 10-65 years old * Histological confirmed ESFT * No previous therapy * ECOG performance status less than 2 * Life expectancy of more than 12 weeks * Normal laboratory values: hemoglobin\>8.0g/dl, neutrophil\>2×109/L, platelet \> 80×109/L, Hb \> 80×1012/L, serum creatine \< 1×upper limitation of normal(ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN Exclusion Criteria: * Pregnant or lactating women * Received treatment for the disease previously * Serious uncontrolled diseases and intercurrent infection * The evidence of CNS metastasis and bone marrow involvement * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * History of allergy to the drugs in this trial * Abnormal LVEF level
References
Publications (0)
Data not yet available
No reference posted for this study.